Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
Tenax Therapeutics announced topline results from its Phase 3 LEVEL trial evaluating oral levosimendan (TNX-103) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The study did not meet its primary endpoint of improvement in 6-minute walk distance or the key secondary endpoint of symp…